By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

AbbVie Inc. v. Hetero USA Inc.
et al.
1:13-cv-00852; filed May 15,
2013 in the District Court of Delaware

• Plaintiff:  AbbVie Inc.
• Defendants:  Hetero USA Inc.;
Hetero Labs Ltd.

Infringement of U.S. Patent
Nos. 7,148,359 ("Polymorph of a Pharmaceutical," issued December 12,
2006), 7,364,752 ("Solid Dispersion Pharmaceutical Formulations,"
issued April 29, 2008), 8,268,349 ("Solid Pharmaceutical Dosage Form,"
issued September 18, 2012), 6,037,157 ("Method for Improving
Pharmacokinetics," issued March 14, 2000), and 6,703,403 (same title,
issued March 9, 2004) following a Paragraph IV certification as part of Hetero's
filing of an ANDA to manufacture a generic version of AbbVie's Norvir®
(ritonavir, used to treat human immunodeficiency virus (HIV) infection).  View the complaint here.

Senju Pharmaceutical Co. Ltd. et
al. v. Strides Inc. et al.
1:13-cv-00851; filed May 15,
2013 in the District Court of Delaware

• Plaintiffs:  Senju Pharmaceutical
Co. Ltd.; Kyorin Pharmaceutical Co. Ltd.; Allergan Inc.
• Defendants:  Strides Inc.;
Agila Specialties Private Ltd.

Infringement of U.S. Patent
No. 6,333,045 ("Aqueous Liquid Pharmaceutical Composition Comprised of
Gatifloxacin," issued December 25, 2001) following a Paragraph IV
certifications as part of defendants' filing of an ANDA to manufacture a
generic version of Allergan's Zymar® (0.3 w/v % gatifloxacin ophthalmic
solution, used for the treatment of bacterial conjunctivitis) and of Allergan's
Zymaxid® (0.5 w/v % gatifloxacin ophthalmic solution, used to treat bacterial
conjunctivitis).  View the complaint here.

Endo Pharmaceuticals, Inc. v.
Par Pharmaceutical Companies, Inc. et al.
1:13-cv-03284; filed May 15,
2013 in the Southern District of New Yorkk

• Plaintiff:  Endo
Pharmaceuticals, Inc.
• Defendants:  Par
Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.

Endo Pharmaceuticals Inc. v.
Sandoz Inc.
1:13-cv-03287; filed May 15,
2013 in the Southern District of New York

Endo Pharmaceuticals Inc. v.
Roxane Laboratories, Inc.
1:13-cv-03288; filed May 15,
2013 in the Southern District of New York

Endo Pharmaceuticals Inc. v.
Mallinckrodt LLC
1:13-cv-03288; filed
May 15, 2013 in the Southern District of New York

Endo Pharmaceuticals Inc. v.
Teva Pharmaceuticals USA, Inc. et al.
1:13-cv-03288; filed May 15,
2013 in the Southern District of New York

• Plaintiff:  Endo
Pharmaceuticals, Inc.
• Defendants:  Teva
Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.; Barr
Laboratories, Inc.

The complaints in these cases
are substantially identical. 
Infringement of U.S. Patent Nos. 7,851,482 ("Method for Making
Analgesics," issued December 14, 2010), 8,309,122 ("Oxymorphone
Controlled Release Formulations," issued November 13, 2012), and 8,329,216
(same title, issued December 11, 2012) following a Paragraph IV certification
as part of defendants' filing of an ANDA to manufacture a generic version of
Endo's Opana® ER CRF (oxymorphone hydrochloride, crush-resistant formulation,
used to treat moderate to severe pain in patients requiring continuous,
around-the-clock opioid treatment for an extended period of time).  View the Par
complaint here.

Bayer Pharma AG et al. v. Par
Pharmaceutical Inc. et al.
1:13-cv-00845; filed May 14,
2013 in the District Court of Delaware

• Plaintiffs:  Bayer Pharma AG;
Bayer Intellectual Property GmbH; Bayer HealthCare Pharmaceuticals Inc.
• Defendants:  Par
Pharmaceutical Inc.; Par Pharmaceutical Companies Inc.

Infringement of U.S. Patent
Nos. 6,362,178 ("2-phenyl Substituted Imidazotriazinones as
Phosphodiesterase Inhibitors," issued March 26, 2002) and 7,696,206 (same
title, issued April 13, 2010) following a Paragraph IV certification as part of
Par's filing of an ANDA to manufacture a generic version of plaintiffs' Staxyn®
(vardenafil hydrochloride, used to treat erectile dysfunction).  View the complaint here.

Astrazeneca AB et al. v.
Watson Laboratories, Inc.- Florida et al.
3:13-cv-03038; filed May 10,
2013 in the District Court of New Jersey

• Plaintiffs:  Astrazeneca AB;
Astrazeneca LP; KBI-E Inc.; Pozen, Inc.
• Defendants:  Watson
Laboratories, Inc.- Florida; Watson Pharma, Inc.; Actavis, Inc.

Infringement of U.S. Patent
Nos. 5,714,504 ("Compositions," issued February 3, 1988), 6,369,085 ("Form
of S-omeprazole," issued April 9, 2002), 6,875,872 ("Compounds,"
issued April 5, 2005), 7,411,070 ("same title," issued August 12
,2008), and 7,745,466 (same title, issued June 29, 2010) following a Paragraph
IV certification as part of Watson's filing of an ANDA to manufacture a generic
version of AstraZeneca's Vimovo® (naproxen and esomeprazole magnesium, used to
relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis, and
ankylosing spondylitis, and to decrease the risk of stomach (gastric) ulcers in
patients at risk of developing stomach ulcers from treatment with non-steroidal
anti-inflammatory drugs (NSAIDs)).  View
the complaint here.

Purdue Pharma L.P. et al. v.
Impax Laboratories, Inc.
1:13-cv-03188; filed May 10,
2013 in the Southern District of New York

• Plaintiffs:  Purdue Pharma
L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.
• Defendant:  Impax
Laboratories, Inc.

Infringement of U.S. Patent
No. 8,337,888 ("Pharmaceutical
Formulation Containing Gelling Agent," issued December 25, 2012) following
a Paragraph IV certification as part of Impax's filing of an ANDA to
manufacture a generic version of Purdue Pharma's OxyContin® (controlled release
oxycodone hydrochloride, used to treat pain). 
View the complaint here.